CRISPR Therapeutics Stock Jumps on Narrower Loss, Pipeline Updates
-
CRISPR Therapeutics (CRSP) stock jumped nearly 14% after reporting encouraging Q3 results.
-
The company posted a narrower net loss of $110 million compared to $176 million loss last year.
-
CRISPR provided updates on several pipeline programs, including potential near-term news on sickle cell disease therapy exa-cel.
-
The company managed to trim operating expenses, helping improve bottom line results.
-
With advancing pipeline and controlled costs, CRISPR convinced investors of progress despite no revenue.